• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AbbVie to Buy Oncology Company Pharmacyclis

Article

AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.

AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall. The North Chicago, Illinois, company said late Wednesday that it will pay $261.25 a share for Pharmacyclics, which makes Imbruvica, a drug approved to treat 3 different types of blood cancers. That represents a premium of about 21% to the closing price of Pharmacyclics shares on Tuesday.

The stock had surged Wednesday after London's Financial Times, citing sources it did not name, reported that competing drugmaker Johnson & Johnson was close to buying Pharmacyclics. That report also cautioned that the J&J deal might unravel.

Read the complete article on ABC News: http://abcn.ws/1BaIYl6

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.